Introduction
Cancer has been the leading cause of death in Korea since 1983 [1] and is the most burdensome disease [2] . More than 210,000 new cancer cases are diagnosed in Korea each year, and cancer is responsible for one in four deaths [3] . This article reports the most recent nationwide cancer statistics in Korea, including incidence, mortality, survival, prevalence, and their trends.
Data sources
The Ministry of Health and Welfare, Korea, initiated a nationwide hospital-based cancer registry called the Korea Central Cancer Registry (KCCR) in 1980. The registry collected 80%-90% of cancer cases annually from more than 180 training hospitals throughout the country.
In 1999, the KCCR expanded cancer registration to cover the entire population under the Population-Based Regional Cancer Registry Program. Details of the history, objectives, [4] . Incidence data for 1999-2012 were obtained from the Korea National Cancer Incidence Database (KNCI DB). The completeness of incidence data for 2012 was 97.7%, as determined by the Ajiki method [5] .
Cancer cases were classified according to the International Classification of Diseases for Oncology, third edition [6] and converted according to the International Classification of Diseases, 10th edition (ICD-10) [7] . A total of 2,405,894 cancer cases first diagnosed between 1993 and 2012 from the KNCI DB were used in the survival analysis, and vital status was followed until December 31, 2013.
Mortality data from 1983 to 2012 were obtained from Statistics Korea [1] . Cause of death was coded and classified according to ICD-10 [7] . Population data were also obtained from Statistics Korea using the resident registration population on July 1 of specified years.
Analysis
Crude rates (CRs) and age-specific rates of cancer incidence and mortality were calculated. Age-standardized rates (ASRs) were calculated using Segi's world standard population [8] . Cumulative risks of cancer, which represent the probability of developing cancer during one's lifetime, were also calculated. Changes in the annual ASRs of cancer incidence were examined by calculating the annual percentage change over a time period as (exp(b)-1)100, where b is the slope of the regression of log ASR for a given calendar year [9] .
Prevalence was also calculated for assessment of cancer burden, which includes new and pre-existing cancer patients Testis  243  243  -13  13  -2,210  2,210  -Kidney  4,152  2,882  1,270  917  663  254  26,015  17,551  8,464  Bladder  3,485  2,798  687  1,221  918  303  25,497  20,754  4,743  Brain and CNS  1,703  933  770  1,186  619  567  8,626  4,508  4,118  Thyroid  44,007  8,052  35,955  373  127  246  258,795  40,921  217,874  Hodgkin lymphoma  264  177  87  64  44  20  2,006  1,281  725  Non-Hodgkin lymphoma  4,553  2,542  2,011  1,523  920  603  26,426  14,299  12,127  Multiple myeloma  1,272  696  576  823  472  351  3,842  2,042  1,800  Leukemia  2,826  1,595  1,231  1,666  919  747  14,890  8,216  6,674  Other and ill-defined  13,010  6,511  6,499  3,679  1,952  1,727  72,177  34,865  37,312 CNS, central nervous system. a) Limited-duration prevalent cases on January 1, 2013; These patients who were diagnosed between January 1, 1999 and December 31, 2012 and were alive on January 1, 2013; Multiple primary cancer cases were counted multiple times, b) Includes the gallbladder and other/unspecified parts of the biliary tract. diagnosed during a given time period who were still alive on an index date. Using the cancer incidence database data from 1999 to 2012, we defined prevalent cases as patients who were diagnosed between January 1, 1999 and December 31, 2012, and were still alive on January 1, 2013. We calculated limited-duration prevalences, namely, 1-and 5-year prevalences. For example, the 5-year prevalence was calculated as the number of people alive on January 1, 2013 who had been diagnosed with cancer within the previous 5 years. We applied this counting method using the SEER*Stat software [10] to calculate the number of cases while adjusting for patients lost to follow-up.
The survival duration for each case was determined as the interval between the date of initial diagnosis and the date of death, date of loss to follow-up, or closing date for followup. Observed survival rates were calculated using the lifetable method and relative survival rates using the Ederer II method [11] were based on an algorithm written in SAS by Paul Dickman [12] , with some minor modifications.
Selected Findings

Incidence
The overall number of incident cancer cases, deaths, and prevalent cases by sex and cancer site for 2012 in Korea are shown in Table 1 
Mortality
A total of 73,759 cancer deaths were reported in Korea for 2012, accounting for 27.6% of all deaths (Table 3 ). In 2012, the CRs per 100,000 for all sites combined were 184.5 and 108.5 in males and females, respectively. The ASRs per 100,000 for all sites combined were 135.2 and 57.7 for males and females, respectively. Cancers of the lung, liver, stomach, and colon/rectum were the main causes of cancer death, together accounting for approximately 61.6% of all cancer deaths in 2012 (Table 4) .
In males, the five most common sites of cancer death in 2012 were lung (CR, 48.3; ASR, 35.1), liver (CR, 33.7; ASR, 24.1), stomach (CR, 24.2; ASR, 17.6), colon and rectum (CR, 18.5; ASR, 13.7), and pancreas (CR, 10.4; ASR, 7.6). In women, lung cancer (CR, 17.8; ASR, 8.9) was the leading cause of cancer death in 2012, followed by colon and rectum (CR, 13.8; ASR, 6.8), stomach (CR, 12.9; ASR, 6.5), liver (CR, 11.3; ASR, 6.1), and pancreas (CR, 8.6; ASR, 4.4).
Trends in cancer incidence
The cancer incidence rates from 1999 to 2012 in Korea for all sites combined and for selected sites are shown in CNS, central nervous system. a) Age-adjusted using the world standard population, b) Includes the gallbladder and other/ unspecified parts of the biliary tract. Includes the gallbladder and other/unspecified parts of the biliary tract. Other and ill-defined Includes the gallbladder and other/unspecified parts of the biliary tract. Lip, oral cavity, and pharynx Includes the gallbladder and other/unspecified parts of the biliary tract. Other and ill-defined Tables 5-7. The incidence for all sites combined increased by 3.3% per year (1.5% in males, 5.3% in females) from 1999 to 2012. The increase in cancer incidence is also illustrated in Fig. 1 . The incidence rates for colorectal and thyroid cancers have continued to increase in both sexes, as have those for prostate cancer in males and breast cancer in females (Fig. 2) . In contrast, the incidences of liver cancer in both sexes, lung cancer in males, and cervical cancer in females have decreased. Notably, thyroid cancer increased rapidly, by 22.3% per year in both sexes, and has been the most common cancer since 2009. Improvements in the sensitivity of diagnostic techniques for thyroid cancer, such as the advent of ultrasound and fine-needle aspiration, have enabled detection of small-sized thyroid cancers, and screening rates have increased. Therefore, the increased incidence of thyroid cancer might reflect the identification of previously undetected diseases rather than a true increase in the occurrence of thyroid cancer [13] [14] [15] [16] . In addition, due to the construction of a 1999-2012 KNCI DB, the completeness of the Korean cancer registry data has shown gradual improvement, and this may have contributed, in part, to the gradual overall increases in cancer incidence, particularly among elderly patients.
The incidence of some cancer sites in 2012, including stomach, colon and rectum, decreased compared to 2011. However, these trends could be causes of random error, therefore, these results should be interpreted with caution.
Age-specific incidence rates
The most common cancer sites by sex and age group in 2012 are shown in Table 8 . Leukemia and thyroid cancer were the most common cancer in both sexes in patients aged 0-14 and 15-34 years, respectively. For males, stomach cancer was the most common cancer in those aged 35-64, while lung cancer was more frequent among patients aged 65 and over. Thyroid cancer was the most common cancer in females aged 35-64 years, and colorectal cancer was the most common cancer among older females aged 65 and over.
The age-specific incidence rates for selected cancers in males and females in 2012 are shown in Fig. 3 . The graphs show that the incidences of stomach, lung, liver, and colorectal cancers increased gradually with age. Incidences of breast CNS, central nervous system.
a)
The incidence rates of ovarian and thyroid cancer are the same in the 0-14 age group. and thyroid cancers in females were highest among patients in their late 40s and early 50s, respectively, and leveled off thereafter. The age-specific pattern of breast cancer is different from those in Western countries [17] .
Trends in cancer mortality
The trends in cancer deaths for all sites combined and for selected sites are shown in Figs. 1 and 4 . ASRs of mortality for all sites combined decreased by 2.7% per year in both sexes since 2002. Lung cancer surpassed stomach cancer as the leading cause of cancer death in 1999 and is expected to account for 22.6% of all cancer deaths in 2012. However, the ASRs of mortality due to lung cancer have decreased slightly in both males and females since 2002. The ASRs of mortality due to stomach and cervical cancers have also shown a continuous decrease. Along with significant increases in prostate and female breast cancer incidence rates, mortality rates of these cancers have also continued to increase. 
Survival rates
The trends in relative survival for all sites combined among both sexes by year of diagnosis from 1999 to 2012 are shown in Fig. 5 . The relative survival for all sites combined increased with year of diagnosis, and also increased when we excluded thyroid cancer cases in our analysis. Table 9 shows the 5-year relative survival rates for four diagnosis periods: 1993-1995, 1996-2000, 2001-2005, and 2008-2012 . The 5-year relative survival rate of patients diagnosed with cancer in the most recent period (2008-2012) was 68.1% for all sites combined in both sexes (59.6% in males and 76.6% in females). When compared with earlier periods, notable improvements in the 5-year relative survival rates were observed for all sites combined. The higher cancer survival rate in females might be explained in part by cancers common in females (e.g., thyroid and breast cancers) having relatively good prognoses.
When examined by year of diagnosis and cancer site, the 5-year relative survival rates appeared to be higher for most major cancers in patients diagnosed from 2008 to 2012 compared with those diagnosed from 1993 to 1995, with the exception of pancreatic cancer. The greatest improvements were seen in cancers of the prostate, stomach, leukemia, lip/oral cavity/pharynx, and non-Hodgkin lymphoma. The improving survival rates could be attributable to early detection and improved treatments [18, 19] Crude prevalence rate: number of prevalent cases divided by the corresponding person-years of observation; Prevalent cases were defined as patients who were diagnosed between January 1, 1999 and December 31, 2012 and who were alive on January 1, 2013; Multiple primary cancer cases were counted multiple times, b)
Age-adjusted using the world standard population, c)
Includes the gallbladder and other/unspecified parts of the biliary tract. treatment could explain the observed absence of improvement in the survival rate for pancreatic cancer [20] .
Prevalence rates
The cancer prevalence rates by sex and cancer site on January 1, 2013 in Korea are shown in Table 10 . The CRs per 100,000 of cancer prevalence for all sites combined were 2,175.0 and 2,730.9 in males and females, respectively, and the ASRs per 100,000 of cancer prevalence for all sites combined were 1,592.2 and 1,788.0 in males and females, respectively. In males, the five leading primary sites of cancer for prevalence were stomach (CR, 546.5; ASR, 391.3), colon and rectum (CR, 410.9; ASR, 296.6), prostate (CR, 194.6; ASR, 141.6), thyroid (CR, 162.5; ASR, 114.8), and liver (CR, 152.6; ASR, 109.7), which together accounted for 67.4% of all prevalent cancer cases. In females, the most common cancer site was thyroid (CR, 866.0; ASR, 600.7), followed by breast (CR, 523.0; ASR, 346.7), colon and rectum (CR, 278.1; ASR, 161.8), stomach (CR, 276.2; ASR, 162.9), and cervix uteri (CR, 173.0; ASR, 111.7), which together accounted for 77.5% of all prevalent cancer cases.
The prevalence by time since diagnosis is shown in Fig. 6 . For all cancers combined, the 2-year prevalence constituted 29.6% of all prevalent cases. The 2-year prevalence, as a percentage of the total prevalence, was highest for thyroid (23.1%), followed by stomach (14.5%) and colon and rectum (13.8%), which had high incidence rates and good prognoses.
For all cancers combined in both sexes, the 2-5-year and > 5-year prevalences accounted for 30.5% and 39.9% of the total prevalence, respectively. The long-term prevalences for lung and liver cancers were relatively low due to low survival rates of lung and liver cancer patients.
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